Enigma of IL-17 and Th17 Cells in Rheumatoid Arthritis and in Autoimmune Animal Models of Arthritis

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2016 Feb 24

PMID 26903711

Citations 38

Authors

Reka Kugyelka

Zoltan Kohl

Katalin Olasz

Katalin Mikecz

Tibor A Rauch

Tibor T Glant

Ferenc Boldizsar

Affiliations

Soon will be listed here.

Abstract

Rheumatoid arthritis (RA) is one of the most common autoimmune disorders characterized by the chronic and progressive inflammation of various organs, most notably the synovia of joints leading to joint destruction, a shorter life expectancy, and reduced quality of life. Although we have substantial information about the pathophysiology of the disease with various groups of immune cells and soluble mediators identified to participate in the pathogenesis, several aspects of the altered immune functions and regulation in RA remain controversial. Animal models are especially useful in such scenarios. Recently research focused on IL-17 and IL-17 producing cells in various inflammatory diseases such as in RA and in different rodent models of RA. These studies provided occasionally contradictory results with IL-17 being more prominent in some of the models than in others; the findings of such experimental setups were sometimes inconclusive compared to the human data. The aim of this review is to summarize briefly the recent advancements on the role of IL-17, particularly in the different rodent models of RA.

Citing Articles

Evaluation of hematological markers as prognostic tools in rheumatoid arthritis.

Masoumi M, Bozorgi M, Nourmohammadi Z, Mousavi M, Shariati A, Karami J BMC Rheumatol. 2024; 8(1):75.

PMID: 39722051 PMC: 11670421. DOI: 10.1186/s41927-024-00444-0.

Extracorporeal photopheresis reduces inflammation and joint damage in a rheumatoid arthritis murine model.

Lin Y, Cheng Z, Zhong Y, Zhao Y, Xiang G, Li L J Transl Med. 2024; 22(1):305.

PMID: 38528553 PMC: 10962138. DOI: 10.1186/s12967-024-05105-x.

Splenectomy at early stage of autoimmune arthritis delayed inflammatory response and reduced joint deterioration in mice.

Khanfar E, Olasz K, Gal S, Gajdocsi E, Kajtar B, Kiss T Clin Exp Immunol. 2024; 216(3):240-251.

PMID: 38363980 PMC: 11097914. DOI: 10.1093/cei/uxae013.

NFIL3 and its immunoregulatory role in rheumatoid arthritis patients.

Du J, Zheng L, Chen S, Wang N, Pu X, Yu D Front Immunol. 2022; 13:950144.

PMID: 36439145 PMC: 9692021. DOI: 10.3389/fimmu.2022.950144.

Integrated Experimental Approach, Phytochemistry, and Network Pharmacology to Explore the Potential Mechanisms of for Rheumatoid Arthritis.

Liu J, Zhang Q, Chen Y, Wang L, Tao T, Ren Q Oxid Med Cell Longev. 2022; 2022:6060677.

PMID: 36160710 PMC: 9499804. DOI: 10.1155/2022/6060677.

References

Martin D, Churchill M, Flores-Suarez L, Cardiel M, Wallace D, Martin R . A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther. 2013; 15(5):R164. PMC: 3979125. DOI: 10.1186/ar4347. View

McInnes I, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs J . Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2013; 73(2):349-56. DOI: 10.1136/annrheumdis-2012-202646. View

Genovese M, Durez P, Richards H, Supronik J, Dokoupilova E, Aelion J . One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol. 2014; 41(3):414-21. DOI: 10.3899/jrheum.130637. View

Li Q, Ren G, Xu L, Wang Q, Qi J, Wang W . Therapeutic efficacy of three bispecific antibodies on collagen-induced arthritis mouse model. Int Immunopharmacol. 2014; 21(1):119-27. DOI: 10.1016/j.intimp.2014.04.018. View

Genovese M, Greenwald M, Cho C, Berman A, Jin L, Cameron G . A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2014; 66(7):1693-704. DOI: 10.1002/art.38617. View

Shiomi A, Usui T, Ishikawa Y, Shimizu M, Murakami K, Mimori T . GM-CSF but not IL-17 is critical for the development of severe interstitial lung disease in SKG mice. J Immunol. 2014; 193(2):849-59. DOI: 10.4049/jimmunol.1303255. View

Jung S, Kim K, Yang C, Park S, Ju J . Cytokine-mediated bone destruction in rheumatoid arthritis. J Immunol Res. 2014; 2014:263625. PMC: 4176903. DOI: 10.1155/2014/263625. View

Papp K, Leonardi C, Menter A, Thompson E, Milmont C, Kricorian G . Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014; 71(6):1183-1190.e3. DOI: 10.1016/j.jaad.2014.08.039. View

van Baarsen L, Lebre M, van der Coelen D, Aarrass S, Tang M, Ramwadhdoebe T . Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?. Arthritis Res Ther. 2014; 16(4):426. PMC: 4292832. DOI: 10.1186/s13075-014-0426-z. View

10.

Ye L, Jiang B, Deng J, Du J, Xiong W, Guan Y . IL-37 Alleviates Rheumatoid Arthritis by Suppressing IL-17 and IL-17-Triggering Cytokine Production and Limiting Th17 Cell Proliferation. J Immunol. 2015; 194(11):5110-9. DOI: 10.4049/jimmunol.1401810. View

11.

Kondo Y, Yao Z, Tahara M, Iizuka M, Yokosawa M, Kaneko S . Involvement of RORγt-overexpressing T cells in the development of autoimmune arthritis in mice. Arthritis Res Ther. 2015; 17:105. PMC: 4436146. DOI: 10.1186/s13075-015-0606-5. View

12.

Kim K, Kim H, Kim B, Cho M, Lee S . Th17 cytokines regulate osteoclastogenesis in rheumatoid arthritis. Am J Pathol. 2015; 185(11):3011-24. DOI: 10.1016/j.ajpath.2015.07.017. View

13.

Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y . Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006; 203(12):2673-82. PMC: 2118166. DOI: 10.1084/jem.20061775. View

14.

Hirota K, Hashimoto M, Yoshitomi H, Tanaka S, Nomura T, Yamaguchi T . T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med. 2007; 204(1):41-7. PMC: 2118414. DOI: 10.1084/jem.20062259. View

15.

Sarkar S, Tesmer L, Hindnavis V, Endres J, Fox D . Interleukin-17 as a molecular target in immune-mediated arthritis: immunoregulatory properties of genetically modified murine dendritic cells that secrete interleukin-4. Arthritis Rheum. 2006; 56(1):89-100. DOI: 10.1002/art.22311. View

16.

Steinman L . A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007; 13(2):139-45. DOI: 10.1038/nm1551. View

17.

Acosta-Rodriguez E, Napolitani G, Lanzavecchia A, Sallusto F . Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol. 2007; 8(9):942-9. DOI: 10.1038/ni1496. View

18.

Yamaguchi Y, Fujio K, Shoda H, Okamoto A, Tsuno N, Takahashi K . IL-17B and IL-17C are associated with TNF-alpha production and contribute to the exacerbation of inflammatory arthritis. J Immunol. 2007; 179(10):7128-36. DOI: 10.4049/jimmunol.179.10.7128. View

19.

Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N . Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med. 2007; 204(12):2803-12. PMC: 2118525. DOI: 10.1084/jem.20071397. View

20.

Singh S, Zhang H, Foley J, Hedrick M, Farber J . Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J Immunol. 2007; 180(1):214-21. DOI: 10.4049/jimmunol.180.1.214. View